Literature DB >> 26202760

Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: difference between HCV genotypes 1b and 2.

Nobuyoshi Seki1, Tomonori Sugita2, Yuta Aida2, Munenori Itagaki2, Haruya Ishiguro2, Satoshi Sutoh2, Hiroshi Abe2, Akihito Tsubota3, Masato Matsushima4, Yoshio Aizawa2.   

Abstract

BACKGROUND: The life cycle of hepatitis C virus (HCV) is tightly associated with host lipoprotein metabolic pathways. Apolipoprotein is present on the outer surface of lipoprotein particles and plays an important role in lipoprotein metabolism. We aimed to elucidate the influence of chronic HCV infection on serum apolipoprotein profiles.
METHODS: Fasting serum apolipoprotein profiles of 310 subjects with active or cleared HCV infection were examined. Subsequently, the association between chronic HCV infection and serum apolipoprotein levels was determined using multiple regression analysis.
RESULTS: Active HCV infection was associated with high serum levels of apo A-II and low serum levels of apo C-II and C-III. HCV infection with both genotype 1b (G1b) and genotype 2 (G2) was associated with low serum levels of either apo C-II and C-III, whereas only HCV G1b infections caused elevated levels of apo A II and E. Among active HCV infections, HCV G1b was associated with an elevation in the serum apo E levels. Furthermore, IL28B non-major genotype (rs8099917 TG/GG) was associated with low levels of serum apo B and high levels of apoA-II, and advanced fibrosis was associated with low levels of apo B and C-II in G1b infection.
CONCLUSIONS: Active HCV infection is distinctively associated with characteristic serum apolipoprotein profiles. The influence on apolipoprotein profiles varies with different HCV genotypes. Moreover, the genotype of IL28B and hepatic fibrosis affected serum apolipoproteins in G1b infection. Abnormalities in serum apolipoproteins may provide a clue to the elucidation of complex interactions between active HCV infection and lipid metabolism.

Entities:  

Keywords:  Apolipoprotein; Genotype; Hepatitis C; Lipid metabolism

Year:  2014        PMID: 26202760     DOI: 10.1007/s12072-014-9572-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  29 in total

1.  Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

Authors:  L Serfaty; T Andreani; P Giral; N Carbonell; O Chazouillères; R Poupon
Journal:  J Hepatol       Date:  2001-03       Impact factor: 25.083

2.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.

Authors:  Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

3.  Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly.

Authors:  Kathrin Hueging; Mandy Doepke; Gabrielle Vieyres; Dorothea Bankwitz; Anne Frentzen; Juliane Doerrbecker; Frauke Gumz; Sibylle Haid; Benno Wölk; Lars Kaderali; Thomas Pietschmann
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

4.  Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.

Authors:  Yoshio Aizawa; Kai Yohizawa; Yuta Aida; Haruya Ishiguro; Hiroshi Abe; Akihito Tsubota
Journal:  Mol Cell Biochem       Date:  2011-08-31       Impact factor: 3.396

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Serum lipid profile of patients with genotype 1b hepatitis C viral infection in Japan.

Authors:  Kyoji Moriya; Yoshizumi Shintani; Hajime Fujie; Hideyuki Miyoshi; Takeya Tsutsumi; Hiroshi Yotsuyanagi; Shiro Iino; Satoshi Kimura; Kazuhiko Koike
Journal:  Hepatol Res       Date:  2003-04       Impact factor: 4.288

7.  PPARdelta increases expression of the human apolipoprotein A-II gene in human liver cells.

Authors:  Petra Thulin; Björn Glinghammar; Josefin Skogsberg; Kerstin Lundell; Ewa Ehrenborg
Journal:  Int J Mol Med       Date:  2008-06       Impact factor: 4.101

Review 8.  Liver injury and disease pathogenesis in chronic hepatitis C.

Authors:  Daisuke Yamane; David R McGivern; Takahiro Masaki; Stanley M Lemon
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

9.  HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus.

Authors:  M Syvänne; J Kahri; K S Virtanen; M R Taskinen
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

10.  Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptors.

Authors:  Jieyun Jiang; Xianfang Wu; Hengli Tang; Guangxiang Luo
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more
  7 in total

Review 1.  Hepatitis C virus relies on lipoproteins for its life cycle.

Authors:  Germana Grassi; Giorgia Di Caprio; Gian Maria Fimia; Giuseppe Ippolito; Marco Tripodi; Tonino Alonzi
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

Review 2.  Chronic hepatitis C virus infection and lipoprotein metabolism.

Authors:  Yoshio Aizawa; Nobuyoshi Seki; Tomohisa Nagano; Hiroshi Abe
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 3.  Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact.

Authors:  Emilie Crouchet; Thomas F Baumert; Catherine Schuster
Journal:  Expert Rev Proteomics       Date:  2017-06-30       Impact factor: 4.250

Review 4.  Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design.

Authors:  Florian Wrensch; Emilie Crouchet; Gaetan Ligat; Mirjam B Zeisel; Zhen-Yong Keck; Steven K H Foung; Catherine Schuster; Thomas F Baumert
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 8.786

5.  Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters.

Authors:  Mary-Anne Doyle; Chrissi Galanakis; Erin Mulvihill; Angela Crawley; Curtis L Cooper
Journal:  Cells       Date:  2019-03-15       Impact factor: 6.600

6.  Impact of Chronic Hepatitis C Virus Genotype 1b Infection on Triglyceride Concentration in Serum Lipoprotein Fractions.

Authors:  Tomohisa Nagano; Nobuyoshi Seki; Yoichi Tomita; Tomonori Sugita; Yuta Aida; Munenori Itagaki; Satoshi Sutoh; Hiroshi Abe; Akihito Tsubota; Yoshio Aizawa
Journal:  Int J Mol Sci       Date:  2015-08-31       Impact factor: 5.923

7.  Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.

Authors:  Takeshi Chida; Kazuhito Kawata; Kazuyoshi Ohta; Erika Matsunaga; Jun Ito; Shin Shimoyama; Satoru Yamazaki; Hidenao Noritake; Tetsuro Suzuki; Takafumi Suda; Yoshimasa Kobayashi
Journal:  Gut Liver       Date:  2018-03-15       Impact factor: 4.519

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.